Kronos Bio Inc (KRON)
$0.95
Live
Performance
- $0.92$0.96$0.95
3.16%
Downside
Day's Volatility :4.65%
Upside
1.54%
- $0.69$1.60$0.95
27.37%
Downside
52 Weeks Volatility :56.88%
Upside
40.63%
Returns
| Period | Kronos Bio Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -24.0% | 3.6% | 0.0% |
6 Months | -1.04% | 10.2% | 0.0% |
1 Year | 5.56% | 19.6% | 0.0% |
3 Years | -94.37% | 16.8% | -23.0% |
Highlights
Market Capitalization | 56.1M |
Book Value | $2.04 |
Earnings Per Share (EPS) | -1.74 |
Wall Street Target Price | 4.13 |
Profit Margin | 0.0% |
Operating Margin TTM | -649.0% |
Return On Assets TTM | -28.28% |
Return On Equity TTM | -63.0% |
Revenue TTM | 8.4M |
Revenue Per Share TTM | 0.14 |
Quarterly Revenue Growth YOY | 44.2% |
Gross Profit TTM | 0.0 |
EBITDA | -94.2M |
Diluted Eps TTM | -1.74 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.35 |
EPS Estimate Next Year | -1.38 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.34 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 334.74%
Technicals Summary
Sell
Neutral
Buy
Kronos Bio Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kronos Bio Inc | -5.0% | -1.04% | 5.56% | -94.37% | -96.49% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kronos Bio Inc | NA | NA | NA | -1.35 | -0.63 | -0.28 | NA | 2.04 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kronos Bio Inc | Buy | $56.1M | -96.49% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Kronos Bio Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 78.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 139.2%
Institutional Holdings
Vida Ventures Advisors, LLC
4.59%Vanguard Group Inc
3.19%Millennium Management LLC
3.08%PARTNERS CAPITAL INVESTMENT GROUP, LLP
2.76%Alphabet Inc
2.39%Wildcat Capital Management, LLC
2.15%
Company Information
kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
Organization | Kronos Bio Inc |
Employees | 58 |
CEO | Dr. Norbert W. Bischofberger Ph.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.95
+0.0%
Invesco Bulletshares 2025 Hi
$0.95
+0.0%
Schwab International Dividend Equity Etf
$0.95
+0.0%
Blockchain Coinvestors Acquisition Corp.
$0.95
+0.0%
Allgiant Travel Company
$0.95
+0.0%
Rogers Corp
$0.95
+0.0%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.95
+0.0%
Iheartmedia
$0.95
+0.0%
Lightpath Technologies Inc
$0.95
+0.0%